SanBio Company Limited (4592.T)
JPY 2299.0
(-0.99%)
JPY 2299.0
(-0.99%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -4.52 Billion JPY | 2.67% |
| 2022 | -4.61 Billion JPY | -2.6% |
| 2021 | -4.37 Billion JPY | 29.3% |
| 2020 | -5.72 Billion JPY | -26.67% |
| 2019 | -5.06 Billion JPY | -77.58% |
| 2018 | -2.78 Billion JPY | 26.34% |
| 2017 | -3.79 Billion JPY | -81.86% |
| 2016 | -2.09 Billion JPY | -86.55% |
| 2015 | -1.14 Billion JPY | -150.91% |
| 2014 | 2.23 Billion JPY | 485.18% |
| 2013 | -585.09 Million JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -1.27 Billion JPY | -1383.31% |
| 2024 Q1 | -664.14 Million JPY | 112.49% |
| 2023 Q4 | -812.06 Million JPY | -949.71% |
| 2023 Q3 | 95.56 Million JPY | 109.66% |
| 2023 Q1 | -934.76 Million JPY | 81.78% |
| 2023 FY | - JPY | 2.66% |
| 2023 Q2 | -989.74 Million JPY | -5.88% |
| 2022 Q4 | -5.13 Billion JPY | -520.97% |
| 2022 Q2 | -1.63 Billion JPY | -286.63% |
| 2022 FY | - JPY | -2.6% |
| 2022 Q1 | 876.94 Million JPY | 156.98% |
| 2022 Q3 | 1.21 Billion JPY | 174.48% |
| 2021 Q4 | -1.53 Billion JPY | -75.79% |
| 2021 FY | - JPY | 29.3% |
| 2021 Q1 | -843.23 Million JPY | 49.82% |
| 2021 Q2 | -1.4 Billion JPY | -66.71% |
| 2021 Q3 | -875.5 Million JPY | 37.72% |
| 2020 Q2 | -1.68 Billion JPY | -13.0% |
| 2020 Q4 | -1.68 Billion JPY | -3.69% |
| 2020 Q3 | -1.62 Billion JPY | 4.02% |
| 2020 FY | - JPY | -26.67% |
| 2020 Q1 | -1.49 Billion JPY | 19.81% |
| 2019 FY | - JPY | -77.58% |
| 2019 Q4 | -1.86 Billion JPY | -52.68% |
| 2019 Q3 | -1.22 Billion JPY | 6.14% |
| 2019 Q2 | -1.3 Billion JPY | -81.71% |
| 2019 Q1 | -715.5 Million JPY | 47.48% |
| 2018 Q4 | -1.36 Billion JPY | -172.65% |
| 2018 Q3 | -499.64 Million JPY | -155.52% |
| 2018 Q2 | -195.53 Million JPY | 76.4% |
| 2018 Q1 | -828.64 Million JPY | -6.91% |
| 2018 FY | - JPY | 26.34% |
| 2017 Q3 | -875.62 Million JPY | 25.6% |
| 2017 Q1 | -1.09 Billion JPY | -213.09% |
| 2017 FY | - JPY | -81.86% |
| 2017 Q4 | -775.06 Million JPY | 11.48% |
| 2017 Q2 | -1.17 Billion JPY | -7.56% |
| 2016 Q3 | -582.61 Million JPY | 35.88% |
| 2016 Q4 | -349.46 Million JPY | 40.02% |
| 2016 FY | - JPY | -86.55% |
| 2016 Q2 | -908.62 Million JPY | -190.32% |
| 2016 Q1 | -312.97 Million JPY | 44.01% |
| 2015 Q3 | -72.25 Million JPY | 80.63% |
| 2015 FY | - JPY | -150.91% |
| 2015 Q1 | -150.04 Million JPY | 12.4% |
| 2015 Q2 | -373.01 Million JPY | -148.61% |
| 2015 Q4 | -558.96 Million JPY | -673.63% |
| 2014 FY | - JPY | 485.18% |
| 2014 Q4 | -171.28 Million JPY | 0.0% |
| 2013 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 958.1 Million JPY | 572.288% |
| PRISM BioLab Co.,LTD | -488.13 Million JPY | -827.003% |
| GNI Group Ltd. | 14.48 Billion JPY | 131.231% |
| Linical Co., Ltd. | 1.24 Billion JPY | 462.803% |
| Trans Genic Inc. | 240.95 Million JPY | 1977.967% |
| MEDINET Co., Ltd. | -1.35 Billion JPY | -233.738% |
| Soiken Holdings Inc. | -583.2 Million JPY | -675.884% |
| Cytori Cell Research Institute, Inc. | -603.09 Million JPY | -650.301% |
| AnGes, Inc. | -8.86 Billion JPY | 48.928% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | -252.005% |
| Nxera Pharma Co., Ltd. | -7.39 Billion JPY | 38.843% |
| Immuno-Biological Laboratories Co., Ltd. | 128.1 Million JPY | 3632.204% |
| NanoCarrier Co., Ltd. | -863 Million JPY | -424.334% |
| Carna Biosciences, Inc. | -1.09 Billion JPY | -314.46% |
| CanBas Co., Ltd. | 53.65 Million JPY | 8534.139% |
| D. Western Therapeutics Institute, Inc. | -775.59 Million JPY | -483.426% |
| RaQualia Pharma Inc. | -111.8 Million JPY | -3947.37% |
| Chiome Bioscience Inc. | -1.21 Billion JPY | -273.431% |
| Kidswell Bio Corporation | -1.38 Billion JPY | -227.704% |
| PeptiDream Inc. | 7.37 Billion JPY | 161.347% |
| Oncolys BioPharma Inc. | -1.92 Billion JPY | -134.494% |
| Ribomic Inc. | -1.01 Billion JPY | -346.902% |
| Healios K.K. | -3 Billion JPY | -50.482% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | -288.15% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | -224.823% |
| Delta-Fly Pharma, Inc. | -1.4 Billion JPY | -222.753% |
| StemRIM | -2.03 Billion JPY | -122.687% |
| CellSource Co., Ltd. | 1.3 Billion JPY | 446.361% |
| FunPep Company Limited | -952 Million JPY | -375.315% |
| Kringle Pharma, Inc. | -888.76 Million JPY | -409.135% |
| Stella Pharma Corporation | -723.85 Million JPY | -525.126% |
| TMS Co., Ltd. | -937 Million JPY | -382.924% |
| Noile-Immune Biotech Inc. | -775.39 Million JPY | -483.577% |
| Cuorips Inc. | -518 Million JPY | -773.552% |
| K Pharma,Inc. | 366.05 Million JPY | 1336.143% |
| Takara Bio Inc. | 8.02 Billion JPY | 156.393% |
| ReproCELL Incorporated | 8.24 Million JPY | 54981.747% |
| PhoenixBio Co., Ltd. | 87.93 Million JPY | 5245.671% |
| StemCell Institute Inc. | 534.35 Million JPY | 946.817% |
| Japan Tissue Engineering Co., Ltd. | 244.81 Million JPY | 1948.342% |
| CellSeed Inc. | -836.51 Million JPY | -440.934% |